Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-naïve and previously treated patients with pemphigus vulgaris after receiving rituximab

Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-naïve and previously treated patients with pemphigus vulgaris after receiving rituximab

Background: Pemphigus vulgaris (PV) is a blistering, life-threatening autoimmune disease. Ethylenediaminetetraacetic acid (EDTA)-treated desmoglein (Dsg) enzyme-linked immunosorbent assay (ELISA) has recently been suggested to detect nonpathogenic antibodies. Rituximab (RTX) is now considered a firs...

Full description

Bibliographic Details
Main Authors: Hoorieh Alaeen, MD, Roja Toosi, MD, MPH, Hamidreza Mahmoudi, MD, Kamran Balighi, MD, Soheil Tavakolpour, MS, Amir Teimoupour, PhD, Maryam Daneshpazhooh, MD
Format: Article
Language:English
Published: Elsevier 2019-12-01
Series:International Journal of Women's Dermatology
Online Access:http://www.sciencedirect.com/science/article/pii/S2352647519300498

Internet

http://www.sciencedirect.com/science/article/pii/S2352647519300498

Similar Items